




September 2009

Volume 14 · Numbers 17/18

pp. 815–908



Cover Story

The featured review in this issue of *Drug Discovery Today*, by Laura Paleari, Alfredo Cesario, Massimo Fini and Patrizia Russo, highlights how the human solid lung cancers, non-small cell lung carcinoma (NSCLC) and malignant pleural mesothelioma (MPM) have a natural history that suggests that they both develop from multiple pre-neoplastic pathways. Their article concentrates on how the natural history of the tumours and lung cancer predisposition may be impacted by the use of nicotinic acetylcholine receptor antagonists, based on the observations that these cancers express nicotinic receptors and that their activation and inhibition results in inhibition and promotion of apoptosis, respectively, in these cells.

DRUG DISCOVERY TODAY

REVIEWS

FOUNDATION

- 822** α 7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and mesothelioma?

Laura Paleari, Alfredo Cesario, Massimo Fini and Patrizia Russo

GENE TO SCREEN

- 837** Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study

Wouter M. Kooloos, Judith A.M. Wessels, Tahar van der Straaten, Tom W.J. Huizinga and Henk-Jan Guchelaar

INFORMATICS

- 845** 'OnePoint' – combining OneNote and SharePoint to facilitate knowledge transfer

Christopher G. Barber, Nuzrul Haque and Ben Gardner

POST SCREEN

- 851** siRNAs: their potential as therapeutic agents – Part I. Designing of siRNAs

Praveensingh B. Hajeri and Sunit Kumar Singh

- 859** siRNAs: their potential as therapeutic agents – Part II. Methods of delivery

Sunit Kumar Singh and Praveensingh B. Hajeri

- 866** The complexity of the GABA_A receptor shapes unique pharmacological profiles

Charlotte D'Hulst, John R. Atack and R. Frank Kooy

- 876** Approaches to seizure risk assessment in preclinical drug discovery

Alison Easter, M. Elizabeth Bell, James R. Damewood Jr., William S. Redfern, Jean-Pierre Valentin, Matthew J. Winter, Carlos Fonck and Russell A. Bialecki

- 885** Targeting mitochondrial apoptosis by betulinic acid in human cancers

Simone Fulda and Guido Kroemer

- 891** Risk-based strategy for the assessment of pharmacokinetic drug–drug interactions for therapeutic monoclonal antibodies

Honghui Zhou and Hugh M. Davis

- 899** Synthetic drugs with anti-ageing effects

Vijay K. Kapoor, Janhvi Dureja and Renu Chadha